Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean 900 39 9?
Displaying drugs 1201 - 1225 of 1830 in total
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
Investigational
Matched Salts cas: … 1218779-75-9
Experimental
Matched Iupac: … (9E)-octadec-9-enamide …
Investigational
Experimental
Investigational
Experimental
Matched Iupac: … 9-(prop-2-en-1-yl)-9-azatricyclo[9.4.0.0^{2,7}]pentadeca-1(15),2,4,6,11,13-hexaene …
Experimental
Matched Iupac: … (9Z)-octadec-9-enoyl chloride …
Experimental
Experimental
Matched Iupac: … [(2S)-2-[(9Z)-hexadec-9-enoyloxy]-3-[(9Z)-octadec-9-enoyloxy]propoxy](2-hydroxyethoxy)phosphinic acid …
GW870086X has been investigated for the treatment of ASTHMA.
Investigational
Dexamethasone isonicotinate is an anti-inflammatory, anti-allergic glucocorticoid that can be administered orally, by inhalation, topically, and parenterally. Its unintended mineralocorticoid action may cause salt and water retention.
Vet approved
DR-01 is a monoclonal antibody directed against human CD94.
Investigational
Lunasine is under investigation in clinical trial NCT02709330 (ALS Reversals - Lunasin Regimen).
Investigational
Matched Iupac: … (2R)-4,8-dimethoxy-9-methyl-2-(propan-2-yl)-2H,3H-furo[2,3-b]quinolin-9-ium …
Lancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis. Lancovutide is a 19-amino-acid tetracyclic peptide produced by Streptoverticillium cinnamoneus and is closely related to cinnamycin (Ro09-0198). It belongs to the lantibiotics. Lantibiotics are bacteriocins that are characterized by the presence of a high proportion of...
Investigational
Matched Iupac: … 41S,44R,47S,50S,53S,56R,65S,70S)-44-amino-47-(4-aminobutyl)-4,16,22-tribenzyl-50-(2-carbamoylethyl)-37
Investigational
Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase family members (IC50 values are 98, 19600, 48700, > 100000 and > 100000 nM for SIRT1, SIRT2, SIRT3, HDAC and NADase respectively). Enhances p53 acetylation in response to DNA damaging agents.
Experimental
Investigational
Displaying drugs 1201 - 1225 of 1830 in total